Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073948 | 0.83 | PDE2A (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL18068091 | 0.83 | KCNK3 (0.35) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12828155 | 0.81 | PGK1 (0.39) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL20642400 | 0.79 | P2RX3 (0.35) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL13073944 | 0.78 | UHRF1 (0.42) | SCN5AAAK1 | |
| SCHEMBL11951673 | 0.77 | P2RX3 (0.33) | P2RX3P2RX2 | |
| SCHEMBL23044965 | 0.75 | SCN5A (0.37) | HRH4SCN5A | |
| SCHEMBL20642466 | 0.75 | PGK1 (0.36) | CYP3A4CYP2C19SCN5A | |
| SCHEMBL19795270 | 0.75 | SCN5A (0.34) | SCN5A | |
| SCHEMBL30932094 | 0.75 | SCN5A (0.37) | HRH4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | CYP3A4 816/4885CYP2D6 525/4885TSHR 3497/4885 |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | CYP3A4 1506/4885CYP2D6 1262/4885TSHR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.